Qualigen Therapeutics, Inc. Quarterly Debt-to-equity in % from Q3 2019 to Q4 2023

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Qualigen Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q3 2019 to Q4 2023.
  • Qualigen Therapeutics, Inc. Debt-to-equity for the quarter ending December 31, 2023 was 938 %, a 1361% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q4 2023 938 +874 +1361% Dec 31, 2023
Q3 2023 287 +240 +516% Sep 30, 2023
Q2 2023 140 +95.5 +212% Jun 30, 2023
Q1 2023 90.3 +43.9 +94.8% Mar 31, 2023
Q4 2022 64.2 +12.4 +24% Dec 31, 2022
Q3 2022 46.5 -11.6 -20% Sep 30, 2022
Q2 2022 44.9 -72.4 -61.7% Jun 30, 2022
Q1 2022 46.3 -309 -87% Mar 31, 2022
Q4 2021 51.8 -19K -99.7% Dec 31, 2021
Q3 2021 58.2 Sep 30, 2021
Q2 2021 117 Jun 30, 2021
Q1 2021 356 Mar 31, 2021
Q4 2020 19K Dec 31, 2020
Q3 2019 281 Sep 30, 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.